Edgar Filing: TETRAPHASE PHARMACEUTICALS INC - Form 4

TETRAPHASE PHARMACEUTICALS INC

Form 4

January 22, 2015

FORM 4

Check this box

if no longer

Section 16.

Form 4 or

subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

OMB APPROVAL

response...

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Macdonald Guy

2. Issuer Name and Ticker or Trading

Symbol

TETRAPHASE

PHARMACEUTICALS INC

[TTPH]

(Last) (First) (Middle) 3. Date of Earliest Transaction

(Month/Day/Year) 01/20/2015

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to

Issuer

(Check all applicable)

_X__ Director 10% Owner X_ Officer (give title Other (specify

below) President and Chief Executive

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

WATERTOWN, MA 02472

480 ARSENAL ST. SUITE 110

(City)	(State)	(Zip) Tab	ole I - Non-	Derivative	Secui	rities Acquii	ed, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securit bor Dispos (Instr. 3, 4	ed of (5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/20/2015		M	10,000 (1)	A	\$ 7.94	60,000	D	
Common Stock	01/20/2015		M	849 (1)	A	\$ 0.87	60,849	D	
Common Stock	01/20/2015		M	22,030 (1)	A	\$ 2.03	82,879	D	
Common Stock	01/20/2015		M	1,256 (1)	A	\$ 5.8	84,135	D	
Common Stock	01/20/2015		S	34,135 (1)	D	\$ 36.5892	50,000	D	

Edgar Filing: TETRAPHASE PHARMACEUTICALS INC - Form 4

(2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactionDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 7.94	01/20/2015		M		10,000	(3)	05/14/2023	Common Stock	10,000
Employee Stock Option (right to buy)	\$ 0.87	01/20/2015		М		849 (1)	<u>(4)</u>	09/10/2019	Common Stock	849
Employee Stock Option (right to buy)	\$ 2.03	01/20/2015		M		22,030 (1)	<u>(4)</u>	09/27/2020	Common Stock	22,030
Employee Stock Option (right to buy)	\$ 5.8	01/20/2015		M		1,256 (1)	<u>(4)</u>	08/07/2018	Common Stock	1,256

Reporting Owners

Reporting Owner Name / Address	Relationships
reporting owner rume, ruuress	

Director 10% Owner Officer Other

Reporting Owners 2

Edgar Filing: TETRAPHASE PHARMACEUTICALS INC - Form 4

Macdonald Guy
480 ARSENAL ST. SUITE 110 X
WATERTOWN, MA 02472

President and Chief Executive

Signatures

/s/ David C. Lubner (as attorney-in-fact for Guy Macdonald)

01/22/2015

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2014.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from \$35.79 to (2) \$38.095 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- (3) Vested as to 25% of the original number of shares granted on 5/15/2014 and further vests as to an additional 6.25% of the original number of shares granted at the end of each successive three-month period thereafter until 5/15/2017.
- (4) Fully vested.
- The number of derivative securities beneficially owned following the transaction reported on this Form 4 has been adjusted to reflect the additional 25,834 incentive stock options owned by the reporting person, and previously reported as a separate option owned by the reporting person, in addition to the non-qualified stock options that were previously reported in the Form 4 filed by the reporting person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3